Revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Labcorp Holdings Inc. (LH)
Price$311.54Cached quote
Net income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.95B | $13.01B | $12.16B | $11.86B | $13.14B | $13.98B | $11.55B | $11.33B | $10.31B | $9.55B | $8.68B | $6.01B | $5.81B | $5.67B | $5.54B | $5.00B | $4.69B | $4.51B | $4.07B |
| Gross profit | $4.01B | $3.62B | $3.36B | $3.71B | $4.99B | $4.95B | $3.25B | $3.18B | $3.09B | $2.85B | $2.90B | $2.20B | $2.22B | $2.25B | $2.27B | $2.10B | $1.97B | $1.87B | $1.69B |
| Gross margin | 28.76% | 27.86% | 27.67% | 31.26% | 38.01% | 35.43% | 28.15% | 28.03% | 29.99% | 29.88% | 33.45% | 36.65% | 38.28% | 39.67% | 41.04% | 41.92% | 41.98% | 41.59% | 41.57% |
| Operating expenses | $2.63B | $2.54B | $2.64B | $2.27B | $1.94B | $2.51B | $1.92B | $1.85B | $1.79B | $1.58B | $1.91B | $1.29B | $1.23B | $1.23B | $1.33B | $1.12B | $1.03B | $1.03B | $914.2M |
| Operating income | $1.38B | $1.09B | $725.6M | $1.44B | $3.05B | $2.45B | $1.33B | $1.33B | $1.31B | $1.27B | $996.8M | $910.4M | $990.9M | $1.02B | $948.4M | $978.8M | $935.9M | $842.9M | $777.0M |
| Operating margin | 9.92% | 8.35% | 5.97% | 12.11% | 23.21% | 17.49% | 11.51% | 11.70% | 12.66% | 13.30% | 11.48% | 15.14% | 17.06% | 18.05% | 17.11% | 19.56% | 19.94% | 18.71% | 19.10% |
| EBITDA | $2.07B | $1.73B | $1.30B | $1.97B | $3.63B | $3.07B | $1.91B | $1.88B | $1.84B | $1.77B | $1.45B | $1.16B | $1.22B | $1.25B | $1.18B | $1.18B | $1.13B | $1.02B | $939.8M |
| EBITDA margin | 14.81% | 13.30% | 10.71% | 16.64% | 27.60% | 21.96% | 16.51% | 16.57% | 17.83% | 18.53% | 16.76% | 19.23% | 21.02% | 22.10% | 21.29% | 23.63% | 24.09% | 22.70% | 23.10% |
| Net income | $876.5M | $746.0M | $418.0M | $1.28B | $2.38B | $1.56B | $823.8M | $883.7M | $1.23B | $711.8M | $437.6M | $511.2M | $573.8M | $583.1M | $519.7M | $558.2M | $543.3M | $464.5M | $476.8M |
| Net profit margin | 6.28% | 5.73% | 3.44% | 10.78% | 18.10% | 11.13% | 7.13% | 7.80% | 11.90% | 7.45% | 5.04% | 8.50% | 9.88% | 10.28% | 9.38% | 11.16% | 11.57% | 10.31% | 11.72% |
| Basic EPSper basic share | $10.54 | $8.89 | $4.80 | $14.05 | $24.60 | $15.99 | $8.42 | $8.71 | $11.99 | $6.94 | $4.43 | $6.03 | $6.36 | $6.09 | $5.20 | $5.42 | $5.06 | $4.23 | $4.08 |
| Diluted EPSper diluted share | $10.46 | $8.84 | $4.77 | $13.97 | $24.39 | $15.88 | $8.35 | $8.61 | $11.81 | $6.82 | $4.35 | $5.91 | $6.25 | $5.99 | $5.11 | $5.29 | $4.98 | $4.16 | $3.93 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 8, 2026Form 4 · 10b5-1 | Kyle Kathryn WEVP, Chief Legal Officer | SellCommon Stock | 762 | $263.89 | $201.1K | 3.8K |
| May 11, 2026Form 4 · 10b5-1 | Schechter Adam HPresident & CEO | SellCommon Stock | 5.9K | $254.50 | $1.50M | 107.2K |
| Mar 27, 2026Form 4 · 10b5-1 | Wilkinson Peter JSVP, Chief Accounting Officer | SellCommon Stock | 1.6K | $267.05 | $436.1K | 1.9K |
| Mar 27, 2026Form 4 · 10b5-1 | Meltzer Jonathan CEVP, Operations | SellCommon Stock | 839 | $267.05 | $224.1K | 3.6K |
| Mar 3, 2026Form 4 | Schechter Adam HPresident & CEO | SellCommon Stock | 8.7K | $279.96 | $2.44M | 80.8K |
Community posts
Labcorp sets new medium-term growth targets and reaffirms its annual outlook
Labcorp ($LH) set medium-term targets for annual revenue growth of 5–8% and adjusted earnings-per-share growth of 8.5–11.5% through 2029. The company also reaffirmed its existing 2026 guidance. The new framework describes the performance ma ...
Labcorp acquires MLM Medical Labs to expand clinical-trial services
Labcorp ($LH) acquired MLM Medical Labs, adding central and specialty laboratory operations in the United States, Germany and South Africa. The company said the purchase expands its biomarker-testing capabilities and improves its ability to ...